White Paper

Novel LipoAvail® Liposomal NMN Elevates 6X NAD+

Overview

Liposomal technology encapsulates active ingredients within liposomes, mimicking intestinal cell membranes for improved absorption and bioavailability.

LipoAvail® NMN, Uthever® NMN powered by LipoAvail® Liposomal Technology, offers the only lab-validated liposomal NMN on the market. After 14 consecutive days, the LipoAvail® NMN group demonstrated 1.74 times higher NAD+ levels in mouse liver tissue and 5.95 times higher NAD+ levels in mouse skeletal muscle compared to the regular NMN group.

Download the Liposome White Paper and catalog for more liposomal product like liposomal VC and glutathione.

This content is provided by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients-Asia.com

Download Now

Latest Content

NMN New Clinical Finding: Obvious NAD(H) Level Increase

Paid for and content provided by Effepharm Ltd

With 7.3% CAGR, The "Nicotinamide Mononucleotide (NMN) Market" size is expected to grow from 194.2 million USD In 2020, to reach 296.5 Million USD by 2026.”

Related Resources

Booth L05 for Clinically Backed NMN & Liposomal VC

27-Aug-2025

Content provided by Effepharm Ltd

White Paper

This year’s Vitafoods Asia, EffePharm will showcase innovative anti-aging solutions, featuring Uthever® NMN, the world’s first large-scale, human clinically-proven NMN brand.

8X Boost in Vitamin C with LipoAvail™

15-Oct-2024

Content provided by Effepharm Ltd

Product Brochure

Vitamin C, a powerful antioxidant, is vital for maintaining normal bodily functions but is unstable and prone to oxidation. As intake increases, the absorption rate of Vitamin C decreases.

Supplier Info Centre

For more product information visit Effepharm Ltd.